A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of a Single Intraoperative Localized Instillation of 4975 [capsaicin; Adlea; ALGRX 4975; Anesiva] in Patients Undergoing Primary Unilateral Total Hip Arthroplasty

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of a Single Intraoperative Localized Instillation of 4975 [capsaicin; Adlea; ALGRX 4975; Anesiva] in Patients Undergoing Primary Unilateral Total Hip Arthroplasty

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2010

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Anesiva
  • Most Recent Events

    • 13 Feb 2009 Planned number of patients changed from 160 to 118 as reported in clinicalTrials.gov record.
    • 13 Feb 2009 Status changed from active, no longer recruiting to discontinued, as reported in clinicalTrials.gov record.
    • 25 Nov 2008 Status changed from recruiting to active, no longer recruiting, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top